Thrombin receptor antagonists
US6063847A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 23, 1998 |
| Grant date | May 16, 2000 |
| Priority date | — |
| Expiry date | Nov 23, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D493/10
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Heterocyclic-substituted tricyclics of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; PA1 the double dotted line represents an optional single bond; PA1 n is 0-2; PA1 Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; PA1 Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; PA1 B is --(CH.sub.2).sub.n3 --, wherein n.sub.3 is 0-5, --CH.sub.2 --O--, --CH.sub.2 S--, --CH.sub.2 --NR.sup.6 --, --C(O)NR.sup.6 --. --NR.sup.6 C(O)--, ##STR2## optionally substituted alkenyl or optionally substituted alkynyl; X is --O-- or --NR.sup.6 -- when the double dotted line represents a single bond, or X is --OH or --NHR.sup.20 when the bond is absent; PA1 Y is .dbd.O, .dbd.S, (H, H), (H, OH) or (H, C.sub.1 -C.sub.6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is .dbd.O, (H, H), (H, OH), (H, SH) or (H, C.sub.1 -C.sub.6 alkoxy); PA1 R.sup.15 is absent when the double dotted line represents a single bond and is H, --NR.sup.18 R.sup.19, or --OR.sup.17 when the bond is absent; or Y is ##STR3## and R.sup.15 is H or C.sub…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.